CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 3,761 enrolled
Drug / intervention
Fecal immunochemical test (FIT)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03264898
NCT03264898N/ACompleted

Comparative Effectiveness of Fecal Immunochemical Tests With Optical Colonoscopy (R01 CA215034)

Barcey T. Levy·observational·Posted Aug 29, 2017·Updated Aug 2, 2024

In Brief

An observational study evaluating Fecal immunochemical test (FIT) for Colorectal Cancer. Completed, enrolled 3,761 participants across 3 sites.

Detailed Summary

Colorectal cancer is a preventable and/or a treatable cancer, but at least 43% of the United States population is not up-to-date with screening. Although 90% of colorectal cancer screening is done using colonoscopy, most other countries use fecal immunochemical tests, reserving colonoscopy for those with a positive fecal immunochemical test. This project will provide the foundation for a paradigm shift for colorectal cancer screening in the United States by identifying how well 5 different FITs work for detecting screening relevant neoplasia, thus reducing morbidity and mortality for colorectal cancer.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedAug 29, 2017
Enrollment StartOct 2, 2017
Primary CompletionMar 7, 2023
Study CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 8.8 years ago

Interventions

Fecal immunochemical test (FIT)device

FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.